Genzyme Transgenics
This article was originally published in The Gray Sheet
Executive Summary
Increase in credit facility by $15 mil. to a total of $24.6 mil. is arranged through a commitment from Fleet Bank. The Framingham, Massachusetts transgenic technology spin-off of Genzyme General also has received a commitment for a $5 mil. lease line of credit with Transamerica Technology Finance. The new capital strengthens the firm's financial position and will be used in part to refinance existing debt and for expansion of production facilities. The company is developing transgenic technology to enable development and production of recombinant proteins and monoclonal antibodies for medical uses
You may also be interested in...
Dr Reddy’s Wants To Break Into Top Five In India
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
Building Trust In Brands Should Be A Continuous Process For The Self-Care Industry
“You can’t just live off the brand equity anymore,” warned J&J's Consumer Health's Minoj Raghunandanan during the ‘Advancing Trust in the Self-Care Industry’ webinar co-hosted by the Global Self-Care Federation and HBW Insight. “You’ve got to continue to build that trust between consumers and products day-in day-out.”
Diversified Sourcing And Sustainability Are Key For Centrient
After almost a year as CEO of Centrient, Rex Clements reflects on the company’s experiences operating amid a pandemic that has underlined the importance of a diversified supply chain, while also highlighting the firm’s sustainable manufacturing initiatives and calling for non-price criteria to be taken into account by procurement processes, in an exclusive interview with Generics Bulletin.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: